Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Qiangda Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0428-5173; OpenAlex author ID A5048153190. Sources: OpenAlex.

Their work

Papers
18 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: 4 papers · 2026: 3 papers

Papers 18

  1. Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Center Study. Co-author DOI 10.1002/advs.202515952↗
  2. Tertiary lymphoid structures in pancreatic cancer: molecular mechanisms, heterogeneity, and clinical significance. First author DOI 10.1016/j.bbcan.2026.189704↗
  3. RASA2 Promotes Pancreatic Cancer Metastasis by Activating TGFβ-Dependent Non-canonical Hedgehog Signaling. First author DOI 10.1158/0008-5472.can-26-0333↗
  4. The Crosstalk with CXCL10-Rich Tumor-Associated Mast Cells Fuels Pancreatic Cancer Progression and Immune Escape. First author DOI 10.1002/advs.202417724↗
  5. The Evolutionary Trajectory and Prognostic Value of GITR+ Tregs Reprogramed by Tumor-Intrinsic PD-1/c-MET Signaling in Pancreatic Cancer. Co-author DOI 10.1002/advs.202500806↗
  6. The CD39-CD73-adenosine axis: Master regulator of immune evasion and therapeutic target in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbcan.2025.189443↗
  7. Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immunoevasive contexture in patients with pan… First author DOI 10.1097/js9.0000000000002733↗
  8. Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer. Co-author DOI 10.1136/jitc-2023-008694↗
  9. Tumor Microenvironment Responsive CD8+ T Cells and Myeloid-Derived Suppressor Cells to Trigger CD73 Inhibitor AB680-Based Synergistic Therapy for Pancreatic Ca… Co-author DOI 10.1002/advs.202302498↗
  10. Current status and future perspectives of clinical research in pancreatic cancer: Establishment of evidence by science. Co-author DOI 10.1002/jhbp.1045↗
  11. Tumor-associated N1 and N2 neutrophils predict prognosis in patients with resected pancreatic ductal adenocarcinoma: A preliminary study. Co-author DOI 10.1002/mco2.183↗
  12. A metabolism-relevant signature as a predictor for prognosis and therapeutic response in pancreatic cancer. Co-author DOI 10.1177/15353702211049220↗
  13. Commentary on "Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic C… Co-author DOI 10.1245/s10434-022-12148-1↗
  14. Lymph Node Metastatic Patterns and Survival Predictors Based on Tumor Size in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1007/s12325-021-01819-2↗
  15. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic c… Co-author DOI 10.1038/s41419-021-04293-4↗
  16. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer. Co-author DOI 10.1111/jcmm.15500↗
  17. Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70. Co-author DOI 10.1177/1758835920953728↗
  18. Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment. First author DOI 10.21037/atm.2019.10.91↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ning Pu · 16 shared papers, 2019–2026 · strength 2.64
  2. Hanlin Yin · 15 shared papers, 2020–2026 · strength 2.56
  3. Wenchuan Wu · 13 shared papers, 2019–2026 · strength 2.14
  4. Wenhui Lou · 11 shared papers, 2020–2026 · strength 1.94
  5. Taochen He · 6 shared papers, 2024–2026 · strength 1.23
  6. Jun Yu · 7 shared papers, 2020–2026 · strength 1.14
  7. Yun Jin · 4 shared papers, 2025–2026 · strength 0.83
  8. Shanshan Gao · 5 shared papers, 2019–2025 · strength 0.63
  9. Wenhui Lou · 4 shared papers, 2019–2022 · strength 0.61
  10. Jiande Han · 3 shared papers, 2024–2025 · strength 0.60
  11. 林尤团 · 1 shared paper, 2026 · strength 0.50
  12. Guozhong Liu · 1 shared paper, 2026 · strength 0.50
  13. Joseph R. Habib · 3 shared papers, 2021–2025 · strength 0.48
  14. Yanfei An · 2 shared papers, 2025–2026 · strength 0.42
  15. Zhihang Xu · 2 shared papers, 2025 · strength 0.41
  16. Yaolin Xu · 2 shared papers, 2025 · strength 0.41
  17. Haibo Wang · 2 shared papers, 2025 · strength 0.41
  18. Wenquan Wang · 2 shared papers, 2023–2025 · strength 0.37
  19. Chenye Shi · 2 shared papers, 2023–2025 · strength 0.35
  20. Liang Liu · 2 shared papers, 2023–2025 · strength 0.35
  21. Huaxiang Xu · 2 shared papers, 2023–2025 · strength 0.35
  22. Sami Shoucair · 2 shared papers, 2022–2025 · strength 0.34
  23. Shangeng Weng · 1 shared paper, 2025 · strength 0.30
  24. Xiaolong Liu · 1 shared paper, 2025 · strength 0.30
  25. Jicheng Zhang · 2 shared papers, 2020–2021 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.